Stocks Health care KLRS
NASDAQ · Health careKalaris Therapeutics, Inc. (KLRS)
It posted a net loss of $44.3M. In fiscal 2025 capital spending exceeded operating cash flow by $38.6M. At June 30, 2026 it held $43.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Kalaris Therapeutics, Inc.
- Net worth
- Kalaris Therapeutics, Inc. has a market value (market cap) of $44.5M at the latest share price, and shareholders' equity of $57.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2020 revenue was $165K, with a net loss of $23.8M.
- Cash flow
- In fiscal 2025 operations used $38.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Kalaris Therapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Kalaris Therapeutics, Inc. does
Kalaris Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker KLRS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$43.4M | -$2.85 | -$38.6M |
| 2024 | n/a | -$69.2M | -$51.77 | n/a |
| 2023 | n/a | -$190.4M | -$185.76 | n/a |
| 2022 | n/a | -$168.7M | -$223.32 | n/a |
| 2021 | n/a | -$172M | -$278.14 | -$106.3M |
| 2020 | n/a | -$69.8M | -$262.91 | -$61M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Kalaris Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 11, 2026
- August 11, 2026
- July 20, 2026
- July 17, 2026
- July 6, 2026
- June 4, 2026
- May 22, 2026Activist stake changed SCHEDULE 13D/A
- May 12, 2026
- May 12, 2026
- April 24, 2026
Insider trades
What the people running Kalaris Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 20, 2026 | Akkaraju SrinivasDirector, 10% owner | Boughtindirect | 244,300 | $1.2M |
| May 20, 2026 | Akkaraju SrinivasDirector, 10% owner | Other changeindirect | 66,906 | - |
| May 20, 2026 | Akkaraju SrinivasDirector, 10% owner | Other changeindirect | 14,937 | - |
| May 20, 2026 | Akkaraju SrinivasDirector, 10% owner | Other changeindirect | 4,471 | - |
| March 20, 2026 | Hagen Brett RChief Accounting Officer | Sold | 1,915 | $12.9K |
| December 22, 2025 | Akkaraju SrinivasDirector, 10% owner | Received as payindirect | 1,500,000 | $15M |
| December 18, 2025 | Akkaraju SrinivasDirector, 10% owner | Boughtindirect | 479,847 | $5M |
Who owns KLRS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Srinivas Akkaraju13D, may seek influence with 4 related filers | 54.2% | May 22, 2026 |
| RTW Investments, LP13G, passive with 1 related filers | 5.7% | February 17, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 57 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Samsara Biocapital, LLC | 12,881,175 | -66,906 |
| Rtw Investments, LP | 1,300,000 | 0 |
| Alyeska Investment Group, L.P. | 572,687 | 0 |
| Siren, L.L.C. | 435,798 | 0 |
| Vanguard Capital Management LLC | 398,712 | +143,364 |
| Ikarian Capital, LLC | 360,000 | 0 |
| UBS Group AG | 262,131 | +255,947 |
| Renaissance Technologies LLC | 149,351 | +83,200 |
| Marshall Wace, Llp | 139,201 | +71,322 |
| Geode Capital Management, LLC | 114,037 | +26,492 |
| Woodline Partners LP | 100,000 | 0 |
| ADAR1 Capital Management, LLC | 100,000 | 0 |
| WHI TRUST Co LLC | 97,493 | 0 |
| Raymond James Financial Inc | 97,164 | -21,723 |
| Citadel Advisors LLC | 95,772 | new |
| Boothbay Fund Management, LLC | 92,261 | 0 |
| Verdad Advisers, LP | 80,297 | new |
| Morgan Stanley | 72,326 | +33,982 |
| Vanguard Fiduciary Trust Co | 66,179 | +29,462 |
| BlackRock, Inc. | 54,442 | +18,399 |
Insiders
1 insiders reported holding 19,408 shares in total, about $36.3K at the last price.
| Holder | Shares |
|---|---|
| Akkaraju SrinivasDirector, 10% owner | 19,40819,408 held indirectly |
Questions about KLRS
What does Kalaris Therapeutics, Inc. do?
Kalaris Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as KLRS. Its shares trade on NASDAQ under the ticker KLRS.
What is Kalaris Therapeutics, Inc.'s net worth?
Kalaris Therapeutics, Inc. has a market value (market cap) of $44.5M at the latest share price, and shareholders' equity of $57.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Kalaris Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $44.3M.
When did Kalaris Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 28, 2026.
When is Kalaris Therapeutics, Inc.'s next earnings report?
Kalaris Therapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare KLRS with
Follow KLRS
Get an email when Kalaris Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Kalaris Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.